Anthony Stephens, MD
Hematology & Oncology · Newburgh, INNPI 1659344117
Payments from drug & device makers
Across 92 payments — averaging $273.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$14K
- Incyte Corporation$5K
- Tosoh Bioscience, Inc.$2K
- Beigene USA, Inc.$1K
- Novartis$1K
- Bristol Myers Squibb$631
- plus $957 from 20 others
What the payments were for
- Consulting fees$3,22516%
- Speaking & faculty fees$12,12561%
- Travel & lodging$820%
- Food & beverage$1,3087%
- Education$1781%
- Gifts$1,91810%
- Other$1,0155%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 20 | $13,810 |
| Incyte Corporation | 4 | $5,319 |
| Tosoh Bioscience, Inc. | 2 | $1,918 |
| Beigene USA, Inc. | 1 | $1,350 |
| Novartis | 19 | $1,185 |
| Bristol Myers Squibb | 3 | $631 |
| Intuitive Surgical | 2 | $192 |
| Amgen | 2 | $119 |
| Johnson & Johnson | 4 | $97 |
| AstraZeneca | 6 | $95 |
| Genentech USA, Inc. | 4 | $59 |
| Exelixis Inc. | 1 | $57 |
| Merck | 3 | $46 |
| Gilead | 3 | $40 |
| Pfizer | 3 | $37 |
| Lilly USA, LLC | 2 | $33 |
| Sanofi | 2 | $30 |
| Eisai Inc. | 2 | $28 |
| Seagen Inc. | 2 | $26 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Tesaro, Inc. | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Bayer | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMPLICITI$7,815
- OPDIVO$4,310
- BRUKINSA$1,350
- 27.29, ST AIA-PACK$959
- CEA, ST, AIA-PACK$959
- 27.29, AIA-Pack Calibrator Set$959
- CEA, AIA-PACK Calibrator Set$959
- PA, ST AIA-PACK$959
- TSH3G, AIA-PACK Calibrator Set$959
- TSH, ST AIA-PACK$959
- PA, AIA-PACK Calibrator Set$959
- Da Vinci Surgical System$132
How this compares
$25,169 in reported general payments places this provider in the 60th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 57 | $704,799 |
| VitrakviLarotrectinib Sulfate | 12 | $476,358 |
| XtandiEnzalutamide | 34 | $475,087 |
| RevlimidLenalidomide | 28 | $471,580 |
| TabrectaCapmatinib Hydrochloride | 16 | $371,500 |
| TagrissoOsimertinib Mesylate | 23 | $362,265 |
| VerzenioAbemaciclib | 19 | $287,535 |
| PomalystPomalidomide | 12 | $280,299 |
| IbrancePalbociclib | 15 | $241,040 |
| KisqaliRibociclib Succinate | 13 | $216,823 |
| MekinistTrametinib Dimethyl Sulfoxide | 13 | $208,789 |
| Abiraterone Acetate | 55 | $126,674 |
| BraftoviEncorafenib | 11 | $101,714 |
| XareltoRivaroxaban | 28 | $24,183 |
| EliquisApixaban | 11 | $9,962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTabrecta, Kisqali, Mekinist | $1,185 | $797,11242 claims |
| BayerVitrakvi | $13 | $476,35812 claims |
| Astellas Pharma US IncXtandi | $14 | $475,08734 claims |
| Bristol Myers SquibbRevlimid | $631 | $471,58028 claims |
| AstraZenecaTagrisso | $95 | $362,26523 claims |
| Lilly USA, LLCVerzenio | $33 | $287,53519 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $13,810 | $280,29912 claims |
| PfizerIbrance, Eliquis | $37 | $251,00326 claims |
| Johnson & JohnsonXarelto | $97 | $24,18328 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $11 | $31529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Newburgh
- Mohammad KhanNewburgh$653K
- Robert SwaneyNewburgh$155K
- Gregory DurmIndianapolis$22.7M
- Nabil AdraIndianapolis$13.2M
- Attaya SuvannasankhaIndianapolis$8.2M
- Zhentao ZhangFort Wayne$6.4M
- Shadia JalalIndianapolis$4.6M
- Ahad SadiqFort Wayne$4M
- Ruemu BirhirayIndianapolis$4M
- Richard GaynorIndianapolis$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.